Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.59 |
| ▸ | HPGD | P15428 | 8/20 | 0.59 |
| ▸ | TSHR | P16473 | 7/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11038432 | 0.86 | HSD17B10 (0.52) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL2659253 | 0.82 | HSD17B10 (0.50) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL157574 | 0.82 | SIRT1 (0.48) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL25828290 | 0.81 | HSD17B10 (0.48) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL1547849 | 0.80 | CYP3A4 (0.56) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL10771021 | 0.79 | HSD17B10 (0.59) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL10769365 | 0.79 | HSD17B10 (0.65) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL7630509 | 0.78 | HSD17B10 (0.44) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL21186739 | 0.75 | HSD17B10 (0.42) | HSD17B10HPGDTSHRMAPK1CASP1 | |
| SCHEMBL54380 | 0.75 | HSD17B10 (1.00) | HSD17B10HPGDTSHRMAPK1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| CN-1052981-C | 1,3,2-phospho heterocyclic octane-novel germicide | UNIV CHINA AGRICULTURAL (CN) | 2000-05-31 | — | — | CN | disclosed |
| CN-1154370-A | 1,3,2-phospho heterocyclic octane-novel germicide | UNIV CHINA AGRICULTURAL (CN) | 1997-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | HSD17B10 2440/4885HPGD 240/4885TSHR 4395/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | HSD17B10 761/4885HPGD 80/4885TSHR 3122/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | HSD17B10 1152/4885HPGD 647/4885TSHR 4091/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | HSD17B10 855/4885HPGD 99/4885TSHR 2963/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | HSD17B10 790/4885HPGD 103/4885TSHR 3004/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | HSD17B10 890/4885HPGD 57/4885TSHR 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.